

Stakeholder Response Form
CRG Product Testing

Please complete one response form per consultation document that you wish to provide comments on.

Date	30 January 2017
Respondent's Name	Beth Barnes
Respondent's Organisation	The Royal College of Ophthalmologists
Replying on behalf of organisation?	Yes
Document responding to:	Interim Clinical Commissioning Policy Proposition: Adalimumab for Adults with Severe Refractory Uveitis
Relevant CRG	Specialised Ear and Ophthalmology CRG

Do you support the proposals within the policy statement?

1. YES ✓
2. NO

Do you have any further comments on the proposal?

1. YES ✓
2. NO

If Yes, please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial 'sense check'.

The proposed interim policy has been carefully considered by the CRG and attempts to allow access to Adalimumab by patients who are experiencing progressive disease which is visually threatening. These patients would have been treated with conventional therapy and either failed to respond or were intolerant to the agents used. The College is highly supportive of this proposal.

However, we seek clarification of the wording of the document to make it absolutely clear if all of the treatment criteria listed have to be met, or just one of them.

Please declare any conflict of interests relating to this document or service area.

N/A